Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$5.53 USD
+0.01 (0.18%)
Updated Jun 27, 2024 04:00 PM ET
After-Market: $5.52 -0.01 (-0.18%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.53 USD
+0.01 (0.18%)
Updated Jun 27, 2024 04:00 PM ET
After-Market: $5.52 -0.01 (-0.18%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum B VGM
Zacks News
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1,933.33% and 85.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Lags Q3 Earnings Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of -16.78% and 1.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alimera Sciences (ALIM) and Deciphera Pharmaceuticals, Inc. (DCPH) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
by Zacks Equity Research
Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
Is Humana (HUM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Humana (HUM) and Alimera Sciences (ALIM) have performed compared to their sector so far this year.
Why Fast-paced Mover Alimera Sciences (ALIM) Is a Great Choice for Value Investors
by Zacks Equity Research
Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Alimera Sciences (ALIM) Is a Great Choice for "Trend" Investors, Here's Why
by Zacks Equity Research
Alimera Sciences (ALIM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alimera Sciences (ALIM) and Centene (CNC) have performed compared to their sector so far this year.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Alimera Sciences (ALIM)
by Zacks Equity Research
Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Has Alimera Sciences (ALIM) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alimera Sciences (ALIM) and Eli Lilly (LLY) have performed compared to their sector so far this year.
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 26.23% and 8.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.87% and 8.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ocugen (OCGN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocugen (OCGN) delivered earnings and revenue surprises of -280% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for April 26th
by Zacks Equity Research
ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022
Trevena (TRVN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and 100.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for March 30th
by Zacks Equity Research
ALIM, APPF, and CNNE have been added to the Zacks Rank #5 (Strong Sell) List on March 30, 2022.
New Strong Sell Stocks for March 28th
by Zacks Equity Research
ALIM, ANIK, and APPF have been added to the Zacks Rank #5 (Strong Sell) List on March 28, 2022
New Strong Sell Stocks for March 1st
by Zacks Equity Research
AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022
Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -55.26% and 0.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -15.38% and -1.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Alimera Sciences (ALIM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 19th
by Zacks Equity Research
ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.
Alimera Sciences (ALIM) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -39.20% and -6.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences (ALIM) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.